Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Sequencing › Guardant Health to Acquire Bellwether Bio

Guardant Health to Acquire Bellwether Bio

Mar 27, 2019
|
staff reporter

NEW YORK (GenomeWeb) - Guardant Health said today that it has entered a definitive agreement to acquire Bellwether Bio, a privately held firm formed two years ago to advance a method for early blood-based cancer detection that relies on detecting epigenetic signals in circulating cell free DNA.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

  2. BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

  3. Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

  4. BioReference Settles False Claims, Kickback Allegations for $11.5M

  5. Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.